EPS for Vericel Corporation (VCEL) Expected At $-0.09

July 13, 2018 - By Mark Mitchell

Vericel Corporation (NASDAQ:VCEL) Logo

Analysts expect Vericel Corporation (NASDAQ:VCEL) to report $-0.09 EPS on August, 8.They anticipate $0.01 EPS change or 12.50 % from last quarter’s $-0.08 EPS. After having $-0.15 EPS previously, Vericel Corporation’s analysts see -40.00 % EPS growth. The stock decreased 10.34% or $1.05 during the last trading session, reaching $9.1. About 1.82M shares traded or 57.02% up from the average. Vericel Corporation (NASDAQ:VCEL) has risen 389.29% since July 14, 2017 and is uptrending. It has outperformed by 376.72% the S&P500.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 3 analysts covering Vericel Corp (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 6 analyst reports since March 5, 2018 according to SRatingsIntel. BTIG Research maintained Vericel Corporation (NASDAQ:VCEL) on Monday, March 5 with “Buy” rating. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Thursday, April 12 by BTIG Research. The stock has “Buy” rating by Leerink Swann on Wednesday, April 4. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Wednesday, June 20 by Leerink Swann. BTIG Research maintained Vericel Corporation (NASDAQ:VCEL) rating on Wednesday, March 28. BTIG Research has “Buy” rating and $1300 target.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $386.13 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

More recent Vericel Corporation (NASDAQ:VCEL) news were published by: Prnewswire.com which released: “Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research” on July 11, 2018. Also Globenewswire.com published the news titled: “Vericel Added to Russell 3000® Index” on June 25, 2018. Streetinsider.com‘s news article titled: “Vericel’s (VCEL) MACI Could See Interest At Upcoming Boston Conference – BTIG” with publication date: July 06, 2018 was also an interesting one.

Vericel Corporation (NASDAQ:VCEL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.